Confronting Today’s Crisis in Antibiotic Development

Feature Articles

Getting Serious About New Antibiotics and Rational Use: Introduction to the Issue by Kathleen Young (Executive Director, APUA)

Dr. Stuart Levy honored with 2012 Abbott-ASM Lifetime Achievement Award

New Antibiotic Development: Barriers and Opportunities in 2012 by Brad Spellberg, M.D. (Assistant Professor of Medicine, David Geffen School of Medicine at UCLA; Antimicrobial Availability Task Force, IDSA)

Resistant Infections: a Tragic Irony in Modern Medicine by Barry Eisenstein, M.D. (Senior Vice President of Scientific Affairs, Cubist Pharmaceuticals) and Elizabeth D. Hermens, PharmD, M.B.A. (President, Society of Infectious Disease Pharmacists)

All Pain, No GAIN: Need for Prudent Antimicrobial Use Provisions to Complement the GAIN Act by Kevin Outterson, J.D. (Associate Professor of Law & Director of the Health Law Program, Boston University; Editor-in-Chief, Journal of Law, Medicine & Ethics)

Fewer Drugs, More Superbugs: Strategies to Reverse the Problem by Jennie Choe, M.S. (Staff Reporter, APUA)

The Lack of Novel Antibiotic and Vaccine Development to Combat Resistance by Victor K.E. Lim, MBBS, M.Sc. (Executive Dean of Medicine and Health, International Medical University of Kuala Lumpur)

APUA One-on-One with Dr. Abraham Sonenshein by Abraham L. Sonenshein, Ph.D. (Professor of Molecular Biology and Microbiology, Tufts University School of Medicine)

Related Initiatives to Spur Antibiotic Development

APUA and ReAct advise new WHO book on antimicrobial resistance
New U.S. FDA guidances on antibiotic use in food animals: mixed reviews
UK-based Antibiotic Action Initiative
BARDA awards $67 million contract to Tetraphase to develop new antibiotic
April 2012 issue of Infection Control & Hospital Epidemiology dedicated to antibiotic stewardship

APUA Partners and Sponsors

APUA Project Partners:
The Bill and Melinda Gates Foundation
The Pew Charitable Trusts
U.S. National Institute of Health (NIH)
Pan American Health Organization (PAHO)
U.S. Agency for International Development
U.S. Department of Agriculture
U.S. Office of Homeland Security
National Biodefense Analysis and Countermeasures Center
World Health Organization (WHO)
Centers for Disease Control and Prevention (CDC)
U.S. Food and Drug Administration
World Bank
Ministries of Health

APUA Corporate Sponsors:
Leadership Level ($25,000+)
The Clorox Company
Benefactor Level ($10,000-$15,000)
Alera Inc.
AstraZeneca
Optimer Pharmaceuticals
Partner Level ($5,000-$10,000)
Alcon Laboratories
Bayer Healthcare Pharmaceuticals
bioMerieux Inc.
GlaxoSmithKline
Supporting Level ($2,500-$5,000)
Paratek Pharmaceuticals

www.apua.org
Confronting Today’s Crisis in Antibiotic Development

About Us
APUA is the leading, independent non-governmental organization with an extensive global field network dedicated to “Preserving the Power of Antibiotics”® and increasing access to needed agents. The APUA Clinical Newsletter has been published continuously three times per year since 1983.
Tel: 617-636-0966 • Email: apua@tufts.edu • Web: www.apua.org

Editors
Stuart B. Levy, Editor
Bonnie Marshall, Associate Editor
Jennie Choe, Assistant Editor (current issue)

Disclaimer
APUA accepts no legal responsibility for the content of any submitted articles, nor for the violation of any copyright laws by any person contributing to this newsletter. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by APUA in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

© 2011 APUA
The material provided by APUA is designed for educational purposes only and should not be used or taken as medical advice. We encourage distribution with appropriate attribution to APUA.

Join the APUA corporate partnership
Join the APUA mailing list